Carregant...
Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
BACKGROUND: Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development, the “biosimil...
Guardat en:
| Publicat a: | Drug Des Devel Ther |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6420106/ https://ncbi.nlm.nih.gov/pubmed/30880912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S170913 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|